AbbVie (ABBV) Depreciation and Depletion (2012 - 2026)

AbbVie has disclosed Depreciation and Depletion across 15 years of filings, most recently posting $188.0 million for Q1 2026.

• In Q1 2026, Depreciation and Depletion rose 3.87% year-over-year to $188.0 million; the TTM figure through Mar 2026 stood at $769.0 million (up 0.92% YoY), while the FY2025 annual figure was $762.0 million, changed 0.26% from the prior year.
• Depreciation and Depletion fell to $188.0 million in Q1 2026, from $203.0 million in the prior quarter.
• Over the last five years, Depreciation and Depletion for ABBV reached as high as $206.0 million in Q4 2024 and fell as low as $179.0 million in Q1 2023.
• The 5-year median for Depreciation and Depletion is $190.0 million (2023), against an average of $190.8 million.
• The widest YoY moves for Depreciation and Depletion: up 13.29% in 2022, down 18.83% in 2022.
• A 5-year view of Depreciation and Depletion shows it stood at $196.0 million in 2022, then dropped by 4.59% to $187.0 million in 2023, then gained by 10.16% to $206.0 million in 2024, then dropped by 1.46% to $203.0 million in 2025, then decreased by 7.39% to $188.0 million in 2026.
• According to Business Quant data, Depreciation and Depletion over the past three periods registered $188.0 million, $203.0 million, and $192.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.